Feavers IM - Search Results

1

History of meningococcal vaccines and their serological correlates of protection.

Vipond C, Care R, Feavers IM. Vipond C, et al. Among authors: feavers im. Vaccine. 2012 May 30;30 Suppl 2:B10-7. doi: 10.1016/j.vaccine.2011.12.060. Vaccine. 2012. PMID: 22607894 Review.

2

An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.

Norheim G, Sanders H, Mellesdal JW, Sundfør I, Chan H, Brehony C, Vipond C, Dold C, Care R, Saleem M, Maiden MC, Derrick JP, Feavers I, Pollard AJ. Norheim G, et al. PLoS One. 2015 Sep 21;10(9):e0134353. doi: 10.1371/journal.pone.0134353. eCollection 2015. PLoS One. 2015. PMID: 26390123 Free PMC article.

3

Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.

Tsolakos N, Lie K, Bolstad K, Maslen S, Kristiansen PA, Høiby EA, Wallington A, Vipond C, Skehel M, Tang CM, Feavers IM, Wedege E, Wheeler JX. Tsolakos N, et al. Among authors: feavers im. Vaccine. 2010 Apr 19;28(18):3211-8. doi: 10.1016/j.vaccine.2010.02.023. Epub 2010 Feb 25. Vaccine. 2010. PMID: 20188677

4

Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.

Alamro M, Bidmos FA, Chan H, Oldfield NJ, Newton E, Bai X, Aidley J, Care R, Mattick C, Turner DP, Neal KR, Ala'aldeen DA, Feavers I, Borrow R, Bayliss CD. Alamro M, et al. Infect Immun. 2014 Jun;82(6):2472-84. doi: 10.1128/IAI.01521-14. Epub 2014 Mar 31. Infect Immun. 2014. PMID: 24686058 Free PMC article.

5

Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines.

Vipond C, Findlay L, Feavers I, Care R. Vipond C, et al. ALTEX. 2016;33(1):47-53. doi: 10.14573/altex.1509291. Epub 2015 Dec 2. ALTEX. 2016. PMID: 26626274 Free article.

6

Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study.

Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, Vipond C, Feavers I. Bryan P, et al. Lancet Child Adolesc Health. 2018 Jun;2(6):395-403. doi: 10.1016/S2352-4642(18)30103-2. Epub 2018 Apr 25. Lancet Child Adolesc Health. 2018. PMID: 30169281

7

Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.

Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Vipond C, et al. Among authors: feavers im. Proteomics. 2006 Jun;6(11):3400-13. doi: 10.1002/pmic.200500821. Proteomics. 2006. PMID: 16645985

8

Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry.

Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J. Vipond C, et al. Among authors: feavers im. Hum Vaccin. 2005 Mar-Apr;1(2):80-4. doi: 10.4161/hv.1.2.1651. Epub 2005 Mar 2. Hum Vaccin. 2005. PMID: 17038831

9

Variation in the Neisseria meningitidis FadL-like protein: an evolutionary model for a relatively low-abundance surface antigen.

Yero D, Vipond C, Climent Y, Sardiñas G, Feavers IM, Pajón R. Yero D, et al. Among authors: feavers im. Microbiology (Reading). 2010 Dec;156(Pt 12):3596-3608. doi: 10.1099/mic.0.043182-0. Epub 2010 Sep 3. Microbiology (Reading). 2010. PMID: 20817647 Free article.

10

Exploring the proteome of meningococcal outer membrane vesicle vaccines.

Wheeler JX, Vipond C, Feavers IM. Wheeler JX, et al. Among authors: feavers im. Proteomics Clin Appl. 2007 Sep;1(9):1198-210. doi: 10.1002/prca.200700204. Epub 2007 Aug 17. Proteomics Clin Appl. 2007. PMID: 21136768

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

120 results

Search Page